AZD 2327

Drug Profile

AZD 2327

Alternative Names: AZD2327

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Depressive disorders

Most Recent Events

  • 27 Jan 2011 Discontinued - Phase-II for Anxiety disorders in USA (PO)
  • 27 Jan 2011 Discontinued - Phase-II for Depressive disorders in USA (PO)
  • 31 Jan 2009 Phase-II clinical trials in Anxiety disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top